These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23162986)

  • 1. Survey draws attention to HYDROmorphone knowledge deficits.
    Alta RN; 2012; 68(3):12-3. PubMed ID: 23162986
    [No Abstract]   [Full Text] [Related]  

  • 2. Teaching from catastrophe: using therapeutic misadventures from hydromorphone to teach key principles in clinical pharmacology.
    Lehmann DF
    J Clin Pharmacol; 2011 Nov; 51(11):1596-602. PubMed ID: 21098693
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlled-release opioids and alcohol.
    Darke AC
    CMAJ; 2006 Jan; 174(3):352. PubMed ID: 16446485
    [No Abstract]   [Full Text] [Related]  

  • 4. The metamorphosis of hydromorphone.
    Reisfield GM; Wilson GR
    J Opioid Manag; 2005; 1(3):139-45. PubMed ID: 17315417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydromorphone: handle with care.
    Borg E
    Can Nurse; 2008 Jan; 104(1):35. PubMed ID: 18286984
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose proportionality of the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR).
    Durnin C; Hind ID; Ghani SP; Yates DB; Cross M
    Proc West Pharmacol Soc; 2001; 44():73-4. PubMed ID: 11794000
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in male and female subjects.
    Durnin C; Hind ID; Ghani SP; Yates DB; Gegg J
    Proc West Pharmacol Soc; 2001; 44():77-8. PubMed ID: 11794002
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of food on the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR).
    Durnin C; Hind ID; Channon E; Yates DB; Cross M
    Proc West Pharmacol Soc; 2001; 44():75-6. PubMed ID: 11794001
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment.
    Durnin C; Hind ID; Wickens MM; Yates DB; Molz KH
    Proc West Pharmacol Soc; 2001; 44():81-2. PubMed ID: 11794004
    [No Abstract]   [Full Text] [Related]  

  • 10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose equivalence of immediate-release hydromorphone and once-daily osmotic-controlled extended-release hydromorphone: a randomized, double-blind trial incorporating a measure of assay sensitivity.
    Cruciani RA; Katz N; Portenoy RK
    J Pain; 2012 Apr; 13(4):379-89. PubMed ID: 22424912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in young and elderly subjects.
    Durnin C; Hind ID; Ghani SP; Yates DB; Cross M
    Proc West Pharmacol Soc; 2001; 44():79-80. PubMed ID: 11794003
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment.
    Durnin C; Hind ID; Ghani SP; Yates DB; Molz KH
    Proc West Pharmacol Soc; 2001; 44():83-4. PubMed ID: 11794005
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of an opioid taper algorithm in hematopoietic progenitor cell transplant recipients.
    Parran L; Pederson C
    Oncol Nurs Forum; 2002; 29(1):41-50. PubMed ID: 11817492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone].
    Sabatowski R; Giesecke T
    MMW Fortschr Med; 2007 Sep; 149 Suppl 3():119-24. PubMed ID: 17955789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules.
    Vashi V; Harris S; El-Tahtawy A; Wu D; Cipriano A
    J Clin Pharmacol; 2005 May; 45(5):547-54. PubMed ID: 15831778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydromorphone-OROS formulation.
    Goforth HW
    Expert Opin Pharmacother; 2010 May; 11(7):1207-14. PubMed ID: 20402557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.
    Shram MJ; Sathyan G; Khanna S; Tudor IC; Nath R; Thipphawong J; Sellers EM
    J Clin Psychopharmacol; 2010 Feb; 30(1):25-33. PubMed ID: 20075644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast milk hydrocodone and hydromorphone levels in mothers using hydrocodone for postpartum pain.
    Koren G
    Obstet Gynecol; 2011 Jun; 117(6):1439. PubMed ID: 21606765
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose proportionality and pharmacokinetics of extended-release (OROS®) hydromorphone: a phase 1, open-label, randomized, crossover study in healthy Taiwanese subjects.
    Vandenbossche J; Richards HM; Lu CC; Richarz U
    Int J Clin Pharmacol Ther; 2014 Mar; 52(3):217-26. PubMed ID: 24472398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.